AXA Economic Audit

Audit Phase: V-ECON — Supply Chain & Economic Forensics
Target Entity: AXA S.A. (Euronext: CS)
Headquarters: Paris, France
Audit Date: May 2026

Supply Chain & Sourcing Relationships

Direct Supplier Relationships

AXA is an insurance and asset management group with no operational involvement in the procurement, importation, or distribution of physical goods. No verified evidence of any commercial relationship with Israeli agricultural exporters — including Mehadrin, Hadiklaim, Galilee Export, or successor entities to Agrexco — has been identified in Israeli agricultural export databases, NGO supply chain investigations, or AXA’s own corporate disclosures ²²¹⁰²⁵. The Who Profits Research Center entry for AXA does not document any agricultural sourcing relationship ²².

No public evidence identified of AXA functioning as a buyer, importer, or supply chain participant for goods originating from Israel or the occupied territories.

Importer of Record Structure

AXA does not operate as an importer of physical goods under any documented corporate structure. No wholly-owned subsidiary or special-purpose import entity for goods originating from Israel or the occupied Palestinian territories has been identified in AXA’s group organisation charts or worldwide directory of operating companies ¹¹¹⁸.

No public evidence identified.

Seasonal Sourcing Patterns

No public evidence identified. The concept of seasonal sourcing is not applicable to AXA’s core business model of insurance underwriting, reinsurance, and asset management.

Third-Party & Indirect Sourcing

AXA’s exposure to Israel is financial in character — manifest through investment holdings, underwriting relationships, and insurance product distribution — rather than through physical goods procurement or any tier of a goods supply chain. No public evidence identified of indirect sourcing of settlement or Israeli-origin goods through third-party vendors, franchisees, or contracted supply partners.

Product Origin, Labeling & Regulatory Compliance

Settlement-Origin Products

AXA does not sell, distribute, or retail physical goods. It therefore incurs no labeling obligation under UK DEFRA guidance on goods produced in Israeli settlements, equivalent EU regulations, or comparable import-marking regimes. No public evidence identified of any AXA product line that would trigger settlement-origin disclosure requirements.

Labeling Compliance

No public evidence identified. Not applicable to AXA’s business model. AXA’s published responsible investment policies address financial instruments and exclusion criteria for controversial weapons ⁷¹⁶; they contain no provisions relating to physical goods labeling, as no such obligation exists for AXA’s operations.

Corporate Labeling Policy

AXA Investment Managers’ exclusion policy ¹⁶ and broader responsible investment framework ⁷ govern investment decisions relating to controversial weapons (including cluster munitions and anti-personnel mines) and other ESG exclusion criteria. These are financial governance instruments, not goods-labeling policies. No public evidence identified of any AXA corporate policy addressing the physical labeling or origin declaration of consumer goods.

Investment, Capital & Financial Exposure

Israeli Banking Sector Holdings

Historical baseline (pre-2020): AXA IM held equity positions across multiple Israeli financial institutions, including Bank Hapoalim, Bank Leumi, Israel Discount Bank (IDB), Mizrahi Tefahot, and First International Bank of Israel, held via AXA IM and AXA Equitable Holdings ⁵¹⁵.

2018–2019 partial divestment cycle: AXA executed partial divestments from Israeli bank holdings during this period. Critically, AXA fully divested its equity stake in Elbit Systems — Israel’s largest domestically-headquartered defense contractor — following sustained campaigning by the BDS Movement and IPSC Ireland ¹²⁶. This divestment is confirmed as completed and is not subject to reversal based on any available disclosure.

September 30, 2023 snapshot: AXA IM retained documented equity positions in Bank Hapoalim, Bank Leumi, and Israel Discount Bank. The aggregate estimated market value of these three holdings stood at approximately US $20.4 million, derived from Refinitiv/LSEG shareholding data compiled in the Ekō and Profundo financial research reports ¹⁵⁴. Holdings in Mizrahi Tefahot and First International Bank of Israel were not confirmed as of this date ¹⁵.

June 24, 2024 divestment: AXA IM’s holdings in Bank Hapoalim and Israel Discount Bank were reduced to zero ²³⁴¹⁵. A residual position of approximately 16,000 shares in Bank Leumi, valued at approximately US $130,000, remained at this date. Profundo and Ekō attributed this residual to passive index-tracking tail positions rather than active strategic investment intent ²³⁴.

Campaign assessment (2024): Ekō and IPSC Ireland characterised the June 2024 divestment milestone as a “near-complete” victory ³¹. BDS Ireland publicly declared it a “huge victory” ¹. BDS Movement campaign materials acknowledge the substantially completed divestment from the banking sector ⁵.

Current status (as of early 2026): Whether the Bank Leumi residual position (~16,000 shares) has been fully wound down between H2 2024 and the present is not confirmed in publicly available sources. This represents a material intelligence gap requiring updated Refinitiv/LSEG shareholder data to resolve.

Defense Industrial Holdings

As of June 30, 2024, AXA IM held an aggregate estimated US $150.43 million in equity and debt instruments of multinational defense contractors whose weapons systems are documented as in use by the Israel Defense Forces ⁵⁶²¹. This figure is sourced from Profundo financial research commissioned in connection with BDS Movement campaign activities ²¹²³.

Confirmed named holdings include: Boeing, General Dynamics, Lockheed Martin, RTX (Raytheon Technologies), Northrop Grumman, BAE Systems, Rolls-Royce, and L3Harris Technologies ⁵⁶²¹. These are equity and/or bond positions; the debt component is estimated at approximately US $71.56 million of the total, though individual instrument vintage and issuance dates are not disclosed in public-facing data — making it impossible to determine from available sources whether bond subscriptions predate or postdate October 7, 2023 ²¹.

Current status: No divestment announcement from AXA regarding this defense portfolio has been publicly documented as of the audit date. Holdings appear ongoing as of mid-2024 based on available evidence.

AXA’s exclusion policy ¹⁶ prohibits investment in manufacturers of cluster munitions, anti-personnel mines, biological and chemical weapons, and nuclear weapons outside recognised nuclear-armed states, but does not categorically exclude conventional defense manufacturers such as those named above ⁷¹⁶.

Venture Capital & Israeli Technology Sector

AXA Venture Partners (AVP): AVP was established under AXA Group sponsorship as a dedicated venture capital fund manager. Israel is explicitly listed as one of AVP’s core operating geographies alongside Europe and North America ⁸. AVP raised a US $150 million second Early Stage fund in 2021 ⁸. AXA’s commitment to AVP as a limited partner investor is documented in trade press coverage ²³.

Neura (Israeli AI/IoT, 2016): AXA Strategic Ventures — AVP’s predecessor entity — led an US $11 million Series A investment round in Neura, an Israeli AI and Internet of Things startup focused on behavioral prediction from connected device data, in 2016 ⁹²⁷. This is a pre-2020 historical data point. Whether AVP or AXA retains any residual equity stake in Neura — or whether Neura has since been acquired, wound down, or undergone an exit — is not confirmed in 2024–2025 public sources.

Co-investment relationships: AVP is documented as having co-invested alongside Liberty Israel Venture Fund and Pitango Venture Capital (Israeli VC) ⁸. Independent verification for these co-investments is sourced from Pitchbook/Crunchbase data; this claim is treated as medium confidence pending live confirmation.

AVP independence process (2024–2025): Trade press coverage from 2024 reports that AVP was pursuing management independence / a management buyout from AXA Group ²³. Whether AXA S.A. retains limited partner (LP) interest in existing AVP fund vehicles after this spin-out process is not confirmed in public filings reviewed. This represents a material structural intelligence gap.

Israeli cybersecurity vertical: AVP lists cybersecurity as a focus investment sector. Specific Israeli cybersecurity portfolio companies beyond Neura are not confirmed by name in publicly available AVP disclosures; only general geographic and sectoral references are available ⁸.

R&D & Innovation Infrastructure in Israel

No evidence of a permanent AXA-branded innovation lab or R&D centre physically located in Israel — comparable to documented AXA Labs facilities in Shanghai or San Francisco — has been identified in corporate filings, press releases, or the AXA worldwide directory ¹⁰¹⁸. AXA’s technology scouting in Israel has operated through the asset-light AVP investment vehicle rather than dedicated physical infrastructure ²⁷⁸. No public evidence identified of an AXA accelerator programme, technology partnership lab, or research facility situated in Israel or the occupied territories.

Sovereign & Corporate Bond Exposure

No public evidence identified of AXA IM holding Israeli sovereign bonds as a disclosed line item in any public reporting reviewed. AXA IM’s exclusion policy ¹⁶ does not categorically exclude Israeli sovereign debt instruments. Whether AXA IM holds Israeli corporate bonds outside the banking sector previously documented is not confirmed in available public sources.

Operational Presence & Market Activity

Insurance Operations in Israel

AXA maintains a local insurance entity in Israel, listed in AXA’s worldwide directory of operating companies ¹⁸. The scope of this entity — including employee count, lines of business written, and gross written premium volume — is not granularly disclosed in English-language public sources or AXA’s consolidated annual reporting ¹⁰²⁵. The entity is treated in AXA’s disclosed corporate geography as one of many local market operating companies without strategic narrative emphasis.

AXA XL (AXA’s global specialty lines, commercial, and reinsurance unit) is documented as operating in the Middle East region with Israel included in its geographic coverage footprint ¹⁷²⁸. AXA XL’s product lines include marine cargo, property, liability, and specialty insurance. Al-Haq’s 2024 report raises the question of whether AXA XL underwrites marine cargo insurance covering US-to-Israel arms shipments ¹⁴; however, no confirming or denying evidence is available in public sources for this specific claim. This remains an unresolved intelligence gap requiring Lloyd’s market records or AXA XL contract-level disclosures to resolve.

AXA Partners operates a global travel and medical assistance network. It is documented as providing travel assistance services and medical emergency cover for policyholders in Israel ¹²¹³²⁰. Whether AXA Partners’ provider network contracts extend to medical clinics located within West Bank settlements is not confirmed in public sources. Al-Haq (2024) identifies this as a structural risk vector for insurance companies operating in the region ¹⁴, but does not document specific AXA reimbursement contracts with settlement-located clinics. This remains an unresolved intelligence gap.

AXA Re and war-risk reinsurance: Whether AXA Re provides war-risk or property catastrophe reinsurance to Israeli domestic insurers (e.g., Harel Insurance, Migdal Insurance) is not publicly disclosed. No evidence confirming or denying such reinsurance treaty arrangements has been identified. No public evidence identified.

Employment & Workforce Contribution

AXA’s global consolidated workforce stands at approximately 147,000 employees as of the 2024 Annual Report ¹⁰. The Israeli operating subsidiary’s headcount is not broken out in English-language consolidated disclosures. No public evidence identified of granular Israeli employment figures, local payroll contribution data, or disclosed tax contribution to the Israeli fiscal system.

Market Positioning & Strategic Characterisation

AXA does not characterise Israel as a “strategic growth market,” “regional hub,” or priority market in any English-language annual report, investor presentation, or press release reviewed ¹⁰²⁵. Israel appears in AXA’s worldwide directory as a standard operating market without the strategic narrative emphasis accorded to AXA’s core geographies — France, the United States, Germany, Switzerland, Belgium, and Hong Kong ¹⁸. No public evidence identified of Israel-specific market strategy language in investor-facing materials.

Corporate Structure & Foundational Ties

Founding & Incorporation History

AXA S.A. was founded in France. Its origins trace to Mutuelles Unies, a French mutual insurance group established in 1817. The group was restructured and rebranded as AXA in 1985 ¹⁰¹⁹. AXA has no Israeli founding origin, no Israeli-origin brand identity, and no acquisition history that roots the group structurally or culturally in Israel ¹⁰. No Israeli-origin entity forms any part of AXA’s documented corporate heritage.

Headquarters & Legal Domicile

AXA S.A. is legally domiciled and operationally headquartered in Paris, France ¹⁰¹⁹. No dual headquarters arrangement or legacy domicile in Israel has been identified. AXA’s legal and regulatory home is France, subjecting the group to French corporate governance law and the Loi de Vigilance (French Duty of Vigilance Law, 2017), which imposes human rights and environmental due diligence obligations on large French companies and their supply chains ²⁴. AXA is subject to monitoring under this framework by civil society organisations including Sherpa and the Business & Human Rights Resource Centre ²⁴.

Ownership Structure & Shareholder Base

AXA S.A. is a publicly listed company on Euronext Paris (ticker: CS) with no single controlling shareholder ¹⁰¹⁹. Major institutional shareholders are large French and international asset managers. The French state holds no documented golden share or special ownership interest in AXA S.A. ¹⁹. No private equity sponsor with a controlling stake has been identified. No Israeli government or Israeli state-affiliated entity holds a documented ownership interest in AXA S.A.

State & Institutional Linkages

• No Israeli government contracts identified in public procurement records or AXA disclosures.
• No Israeli government board appointees identified in AXA S.A. governance disclosures ¹⁰.
• No designation of AXA as critical national infrastructure in Israel. No public evidence identified.
• No French state golden share or comparable charter mechanism linking AXA to state policy objectives documented ¹⁹.

Structural Governance Features

No golden shares, super-voting founder shares, or charter restrictions tying AXA to Israeli state objectives have been identified in AXA’s articles of association or governance documentation ¹⁹. No public evidence identified of structural governance mechanisms linking AXA’s corporate mission or investment mandate to Israeli government policy.

Profit Repatriation & Economic Contribution

Revenue Attribution

AXA does not disclose Israel-specific revenue as a standalone geographic segment in its annual reports or Universal Registration Documents ¹⁰²⁵. Israel’s premium income and fee revenue falls within aggregated “International” or broader regional reporting buckets that are not individually itemised at the single-country level in public disclosures reviewed. No public evidence identified of a disclosed Israel-specific revenue figure.

Profit Flows & Repatriation Direction

AXA S.A.’s group ownership structure directs consolidated global profits upward to the French-domiciled parent entity ¹⁰¹⁹. Where AXA’s Israeli operating subsidiary generates underwriting profit, dividends would flow upward to AXA S.A. in Paris in the standard subsidiary-to-parent repatriation direction — meaning profits are extracted from Israel to France, not directed into Israel from AXA’s global operations. No evidence identified of Israeli-domiciled beneficial ownership receiving profit flows from AXA’s non-Israeli global operations.

Economic Ecosystem Role

No public evidence identified of any Israeli government body, industry association, or independent assessment designating AXA as a “key employer,” “anchor institution,” or “strategic infrastructure provider” within any sector of the Israeli economy. AXA’s Israeli operation is consistent with the profile of a standard local market insurer operating in one of many countries globally, without documented national economic significance in the Israeli context ¹⁸¹⁰.

Tax Contribution

No public evidence identified of disclosed Israeli tax contribution, Israeli tax registration details at subsidiary level, or country-by-country reporting for Israel in AXA’s consolidated financial disclosures. Country-by-country tax reporting, where it exists in AXA’s filings, does not itemise Israel as a separate disclosure jurisdiction in publicly available materials reviewed ¹⁰²⁵.

End Notes